Xenetic Biosciences (XBIO) SC 13D Xenetic Biosciences / CLS Therapeutics ownership change

Exhibit 1

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k)(1)(iii) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned company and individuals agree to the joint filing on behalf of each of them of a Schedule 13D (including amendments thereto) with respect to the Common Stock of Xenetic Biosciences, Inc. This Joint Filing Agreement shall be filed as an Exhibit to such Statement.

June 14, 2023

Date

CLS Therapeutics, LLC.

/s/ Georgy Tets

Signature

Georgy Tets, MD, PhD, Chief Executive Officer

Name/Title

CLS Therapeutics, LLC

/s/ Georgy Tets

Signature

Georgy Tets, MD, PhD, Director

Name/Title

/s/ Dmitry Genkin

Signature

Dmitry Genkin

Name

/s/ Victor Tets

Signature

Victor Tets

Name

/s/ Georgy Tets

Signature

Georgy Tets, MD, PhD

Name

/s/ M. Scot Maguire

Signature

M. Scot Maguire

Name